Overview
2. Non-myeloablative allogeneic transplants for hematologic malignancies and solid tumors.
3. Supportive care for hematopoietic stem cell transplants.
4. Prevention and therapy of graft versus host disease.
Current Appointments & Affiliations
Professor of Medicine
·
2021 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Recent Publications
Correction: High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Journal Article Bone Marrow Transplant · September 2025 Full text Link to item CiteFood insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes.
Journal Article Bone Marrow Transplant · June 2025 Food insecurity (FI), defined as the lack of continuous access to adequate food, affects 17-55% of cancer patients. Effects may be exacerbated in hematopoietic stem cell transplant (HSCT) patients, who face nutritional challenges due to treatment side effe ... Full text Link to item CiteExploring facilitators and barriers to daily chlorhexidine gluconate bathing in adult patients undergoing hematopoietic stem cell transplantation.
Journal Article Support Care Cancer · November 28, 2024 UNLABELLED: Hematopoietic cell transplantation (HCT) is a promising treatment for hematologic malignancies, but intensive conditioning leads to immunosuppression and susceptibility to healthcare-associated infections (HAI). Despite standard prevention meas ... Full text Link to item CiteRecent Grants
An Open-label Pilot Multicenter Study to Evaluate the Safety and Efficacy of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms
Clinical TrialPrincipal Investigator · Awarded by ADC Therapeutics Sarl · 2020 - 2025A Phase I Open Label Study of Panobinostat in combination with Lenalidomide, Bortezomib, and Dexamethasone in patients with relapsed and relapsed/refractory Multiple Myeloma
Clinical TrialPrincipal Investigator · Awarded by Dana-Farber/Partners CancerCare, Inc. · 2014 - 2023A Randomized, Dbl-Blind, Placebo-Controlled, Parallel-Grp, Multictr, Ph 3 Study-Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients
Clinical TrialPrincipal Investigator · Awarded by Chimerix, Inc. · 2013 - 2016View All Grants
Education, Training & Certifications
Wake Forest University ·
1983
M.D.
Wake Forest University ·
1979
M.S.